This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.
|Eligibility criteria|| |
|Study details|| |
This study requires tumour tissue and blood tests close to the date of the lung cancer surgery. This assessment determines the eligibility for the trial.
There is close follow up with blood tests after completion of intial chemotherapy. If eligible for the trial the patient is randomised to durvalumab or placebo.
While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.
|Further information|| |
For more information regarding this clinical trial click here.
North Shore NSW